Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "quarter"

976 News Found

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22
News | November 10, 2021

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.


Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22
News | November 09, 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Amneal Pharmaceuticals acquires Puniska Healthcare for Rs 700 crore
News | November 09, 2021

Amneal Pharmaceuticals acquires Puniska Healthcare for Rs 700 crore

The company has operations in North America, Asia, and Europe,


U.S. FDA approves ANI’s purified cortrophin gel
Biotech | November 03, 2021

U.S. FDA approves ANI’s purified cortrophin gel

Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016


AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
Biotech | November 02, 2021

AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma

The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio


Caplin Point Labs posts  Q2FY22 PAT at Rs 74.98 Cr
News | November 02, 2021

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Lyka Labs  Q2FY22 consolidated PAT at Rs. 28.43Cr
News | November 01, 2021

Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr

Lyka Labs has reported consolidated financial results for the period ended September 30, 2021


Glamyo Health widens its dental treatment portfolio
Startup | November 01, 2021

Glamyo Health widens its dental treatment portfolio

Clear aligners are a series of tight-fitting custom-made mouthpieces or orthodontic systems that are useful in correcting misaligned or crooked teeth